Tai long Pharmaceutical (600222) answered investors' questions on the investor relations platform on January 12.
Investors: after the major shareholders of the company are in place, will they step up efforts to promote traditional Chinese medicine? In addition to capital assistance, will major shareholders support the company in the company's products and markets?
Tai long Pharmaceutical Secretary: Hello, dear investors, the addition of new strategic investors will provide stronger support to the company in terms of funds and resources, and will better promote the strategic development and implementation of the company in the fields of traditional Chinese medicine, CXO and big health, and promote the high-quality development of the pharmaceutical industry in the region. The company will also continue to focus on the traditional Chinese medicine industry, build the CXO service system of pharmaceutical research and development in the whole industry chain, strengthen the input of core technology and strategic resources, maintain the sustainability and stability of the development strategy, strengthen the research and development and introduction of new products in the traditional Chinese medicine sector, and rapidly form a series of product combinations with Shuanghuanglian oral liquid as the leader. At the same time, it will be further extended in the field of health of traditional Chinese medicine. Expand more new health products of traditional Chinese medicine to form a new profit growth point. Thank you for your attention to the company!
Investors: traditional Chinese medicine collection results, Tailong Shuanghuanglian oral liquid won the bid 19 provinces, will it have a positive effect on the performance in 2022? According to media analysis, Shuanghuanglian single product collection income may exceed 1 billion yuan, does the company have sufficient production capacity to support market demand?
Tai long Pharmaceutical Secretary: dear investors, winning the bid is conducive to the rapid realization of the company's supply to more than 2000 grade hospitals in 19 provinces, and will greatly increase the coverage of this kind of products in medical institutions, and the company will be prepared in advance. There is sufficient production capacity to meet the new market demand in the future, ensure product supply, and strive for opportunities to achieve breakthroughs in traditional Chinese medicine products such as Shuanghuanglian Oral liquid. Give back to the majority of shareholders with better performance. Thank you for your attention to the company!
Investor: Hello, Dong Mi, is there any new traditional Chinese medicine preparation besides Shuanghuanglian oral liquid? What are the main diseases to be treated?
Tai long Pharmaceutical Secretary: Hello, dear investors, the company's traditional Chinese medicine products are divided according to their functions. The main products with heat-clearing and detoxifying effect are: Shuanghuanglian oral liquid series, Shuanghuanglian mixture, Qingrejiedu oral liquid, cough-relieving orange oral liquid, purging heat mixture and so on. Shuanghuanglian oral liquid (children's type), children's heat-clearing and cough-relieving oral liquid are used for children. In addition, the company also has salvia miltiorrhiza oral liquid (promoting blood circulation and removing blood stasis, dredging pulse and nourishing heart), Wujin oral liquid (for the treatment of stomach cold and pain, gastric and duodenal ulcer, bleeding) and other products. The company is also continuing to carry out the research and development of traditional Chinese medicine products based on classic prescriptions. at the same time, the products introduced by the company, such as Huoxiang Zhengqi mixture, Banlangen syrup, Wuzi Yanzong oral liquid, Shengmai Yin (Dangshen Fang), and Honeysuckle Flowers are being transferred, and the company's portfolio of traditional Chinese medicine products will be further expanded after completion. Thank you for your attention to the company!
According to the third quarterly report of Tailong Pharmaceutical Company in 2021, the company's main income was 1.118 billion yuan, up 15.8% from the same period last year; the net profit was 28.2991 million yuan, up 12.45% from the same period last year; and the non-net profit was 29.8477 million yuan, up 37.51% from the same period last year. Among them, in the third quarter of 2021, the company's main income in a single quarter was 366 million yuan, up 15.26% from the same period last year; and the net profit in a single quarter was 1.1175 million yuan, up 170.59% from the same period last year. The non-net profit in a single quarter was 2.9706 million yuan, up 164.17% from the same period last year; the debt ratio was 55.31%, the investment income was 3.5516 million yuan, the financial expenses were 65.5944 million yuan, and the gross profit margin was 28.38%.
The stock has no agency rating in the last 90 days. In the past three months, the net inflow of financing was 26.4551 million, and the financing balance increased, while the net inflow of securities was 178600, and the balance of securities lending increased. According to the Securities Star valuation analysis tool, Tai long Pharmaceutical (600222) has a good company rating of 1.5 stars, a good price rating of 1 star, and a comprehensive valuation rating of 1.5 stars. (rating range: 1-5 stars, up to 5 stars)
Tai long Pharmaceutical owner's business: research, development, production and sale of proprietary Chinese medicine and western medicine.
The chairman of the company is Li Jingliang. Mr. Li Jingliang: born in January 1969 with a master's degree, he once served as the general manager of the company, vice chairman of the company and chairman of Zhongsheng Group. He is currently the chairman of the company.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.